Rapid and significant symptom improvement with JAKAVI
Significant improvement in Total Symptom Score with JAKAVI compared with placebo1
COMFORT-I: Patients with >50% improvements in TSS with JAKAVI vs placebo at Week 241

Adapted from: Verstovsek S et al. N Engl J Med. 2012;366:799-807.1
A 50% improvement is clinically relevant.
- Patients treated with JAKAVI had a 46.1% mean improvement in TSS, while patients treated with placebo had a 41.8% mean worsening of score (P<0.001)1
Patients treated with JAKAVI had improvement in individual symptoms compared with placebo and with BAT1,2
COMFORT-I: Improvement from baseline in MFSAF score with JAKAVI vs placebo at Week 241

Adapted from: Verstovsek S et al. N Engl J Med. 2012;366:799-807.1
Based on a post hoc analysis. Number of patients varied per symptom score; JAKAVI: n=98 to 124, placebo: n=77 to 100.
COMFORT-II: Improvement from baseline in EORTC QLQ-C30 symptom score with JAKAVI vs BAT at Week 482

Adapted from: Harrison C et al. N Engl J Med. 2012;366:787-798.2
Based on prespecified exploratory analyses. JAKAVI (n=146) and BAT (n=73).
JAKAVI Treatment in Clinical Practice: Addressing previously unrecognized symptom burden
Myelofibrosis symptoms are frequent and severe; however, symptoms also can develop gradually over time and so may not be fully appreciated by patients. Watch the video below to learn more from Dr Ruben Mesa about the importance of discussing potential symptoms with patients in order to effectively manage disease and restore quality of life.